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Uveal melanoma (UM) is the most common primary intraocular cancer in adults. In the pres-
ent study, we aimed to characterize the immunological features of primary UM cancer and
to provide an association with prognostic markers and outcome. Also, we assessed the
influence of the microenvironment on the expression of inhibitory immune checkpoints in
UM. Genes of interest included MHC Class I and Class II molecules, as well as inhibitory
immune-checkpoints, i.e. PDL1, PDL2, B7-H3, B7-H4, TBFRSF6B, CD47, CD155, GAL9,
HVEM and CD200. We observed significant lower levels of MHC genes in UM cells as com-
pared to normal uveal melanocytes. Unexpectedly however, the expression levels of most
of the analyzed inhibitory immune-checkpoint genes were not different in cancer cells as
compared to normal melanocytes, with the exception of CD200 and HVEM, that resulted
significantly reduced. On the other hand, PDL1 inversely correlated with OS, PFS and thick-
ness of the tumor. Also, PDL1, along with PDL2, expression significantly increased under
inflammatory conditions. Finally, for the first time, we propose a possible role for CD47 in the
immune evasive properties of UM. We show here that CD47 is significantly upregulated by
UM cells following inflammatory stimuli and that it represents a good independent predictor
of disease progression. The results from this study may propel advances in the development
of immune-based therapies for UM patients.
Introduction
Uveal melanoma (UM) is the most common primary intraocular cancer in adults [1,2]. The
5-year survival rate is between 50% and 70% and up to 50% of patients develop metastases
within 36 months with a median survival of 6 months after metastasis occurrence [1,2]. Unfa-
vorable prognostic markers are the presence of epithelioid cells, large tumor diameter, anterior
localization and chromosome 3 monosomy. Also, on the contrary to other cancers, the pres-
ence of tumor-infiltrating lymphocytes is associated to a poor outcome [3–5].
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Recently, UMs have been classified as either Class 1 (with low metastatic risk) or Class 2
(with high metastatic risk), based on the transcriptomic profile of 12 genes. Class 1 UMs are
further divided into Class 1a and Class 1b, the latter bearing a worse prognosis. Furthermore,
the preferentially expressed antigen in melanoma (PRAME) gene has been reported to be an
independent prognostic biomarker [6]. The liver accounts for 80–91% of the metastases.
Although both cutaneous melanomas and UM originate from the melanocyte, their clinical
behavior and underlying molecular mechanisms differ significantly [7]. For example, unlike
cutaneous melanoma where metastasis to the central nervous system (CNS) occur in 40–60%
of cases, only 4–15% of UM metastasize to CNS. The reasons for this discrepant metastatic pat-
tern have so far not been dismantled.
The better understanding of biological differences and gene signatures between cutaneous
and UM are clearly important to identify the factors that confer lower CNS metastatic poten-
tial to uveal vs. cutaneous melanoma.
Standard of care treatment of UM is represented by local radiation therapy, i.e. brachyther-
apy or charged-particle and proton-beam radiation, and enucleation for very large tumors
[1,2]. For metastatic UM, no FDA-approved standard of care is available [6]. While the devel-
opment of immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated anti-
gen 4 (CTLA-4) and programmed cell death-1 (PD-1), have dramatically increased the
outcome for patients with advanced cutaneous melanoma, a comparable clinical benefit has
not been observed for unresectable/metastatic UM. This can be partly explained by the obser-
vation that TILs from cutaneous melanoma have higher anti-tumor reactivity as compared to
those from UM samples [8]. It is believed that since the eye is an immune privileged site, the
tumor and its metastases show local immune-suppressive and immune-evasive features that
affect the efficacy of current immunotherapies [9–12].
In the present study, we aimed to characterize the immunological features of primary UM
cancer and to provide an association with prognostic markers and outcome. Also, we assessed
the influence of the microenvironment on the expression of inhibitory immune checkpoints
in UM. The results from this study may propel advances in the development of immune-based
therapies for primary and recurrent UM cases.
Materials and methods
Immunological profiling of uveal melanoma
In order to evaluate the immunological differences between UM and normal uveal melano-
cytes, the publicly available GSE62075 dataset was obtained from Gene Expression Omnibus
(GEO, https://www.ncbi.nlm.nih.gov/geo/). GSE62075 included gene expression profiling of
three primary cultures of human uveal melanocytes and of three human UM cell lines, the
T115, T142 and T143 cells, at low culture passages (between 2 and 7). The G4851A SurePrint
G3 Human GE 8x60 K array slide platform was used. Detailed description of the experimental
design and procedures can be retrieved from the relative publication [13]. Data were analyzed
using LIMMA (Linear Models for Microarray Analysis) and genes with a Benjamini & Hoch-
berg false discovery rate<0.05 were considered to be significant.
Immunological changes in uveal melanoma under inflammatory
conditions
To determine whether pro-inflammatory factors from activated T cells altered the immunolog-
ical profiling of UM, the GSE55983 microarray dataset was used. GSE55983 included data
from the three primary human UM cell lines, Mel290, Mel270 and 92.1. CD3+ T cells were
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isolated from whole blood of healthy donors, activated using anti-CD3/CD28 antibodies and
cultured in 0.4 μm membrane inserts over UM cell lines, for 64 hours. After the incubation
period, total RNA was collected from the UM cell lines and genome-wide transcriptomic
expression was obtained using the Affymetrix Human Gene 1.0 ST microarray platform [14].
Identification of clinical predictors
Genes of interest included MHC Class I and Class II molecules, as well as inhibitory immune-
checkpoints, i.e. PDL1, PDL2, B7-H3, B7-H4, TBFRSF6B, CD47, CD155, GAL9, HVEM and
CD200 [15]. In order to evaluate whether the expression levels of inhibitory immune-check-
points and HLA genes in UM are able to predict prognosis or are associated to relevant clinical
features, RNA Seq data from the TCGA datasets were downloaded through the cBioportal
web-based utility (http://www.cbioportal.org; http://bit.ly/2HAJyjG). Data from 80 primary
tumors, with no neoadjuvant therapy prior to excision were selected. Clinical data included
metastasis free survival, overall survival, tumor diameters, BAP1 mutations and mitotic count.
Statistical analysis
Gene expression differences between normal uveal melanocytes and UM were evaluated using
unpaired two-tailed Student’s t test. Enrichment of the “Immune Response” Biological Process
(GO:0006955) among the significantly modulated genes in GSE62075 was calculated using an
hypergeometric test. Paired two-tailed Student’s t test was used to assess differences in gene
expression in UM cells following pro-inflammatory stimulation. Statistical correlation between
two continuous variables was calculated by partial correlation accounting for disease status,
histological type, BAP1 mutation and adjuvant therapy. For each gene, predicted values were
obtained by Multivariate General Linear Model using BAP1, Histological type and Adjuvant
therapy as Fixed Factors and Mitotic count, Basal Diameter and Thickness as Covariates.
Receiver Operating Characteristic (ROC) curves were constructed using disease status (recur-
rent disease) as nominal variable. Survival analysis was performed using Kaplan-Meier and its
significance analyzed by log-rank (Mantel-Cox) test. Continuous variables were dichotomized
using median value as cut off. For all the analysis, a p-value<0.05 was considered statistical
significant. Statistical analysis was performed with GraphPad Prism 5 (GraphPad Software,
San Diego, C, US) and SPSS 24 (IBM SPSS Statistics, IBM Corporation, Armonk, NY, US).
Results
Modulation of immune-related molecules in uveal melanoma
Analysis of GSE62075 revealed that in UM, 417 genes are significantly modulated as compared
to normal uveal melanocytes. Fifty-five genes resulted in common with genes belonging to the
“Immune Response” Biological Process (GO:0006955), reaching a strong statistical signifi-
cance (p<0.001) (Fig 1A). Next, we wanted to compare the expression of MHC Class I and
Class II molecules, as well as inhibitory immune-checkpoints, i.e. PDL1, PDL2, B7-H3, B7-H4,
TBFRSF6B, CD47, CD155, GAL9, HVEM and CD200, in UM in comparison to normal uveal
melanocytes. MHC class I molecules resulted significantly downregulated in UM as compared
to normal uveal melanocytes (Fig 1B), while no differences were observed for the MHC Class
II genes, with the exception for HLA-DPA1 (Fig 1C). As regards the immune checkpoints
investigated, no modulation was observed for PDL1, PDL2, B7-H3, B7-H4, TBFRSF6B, CD47,
CD155, and GAL9 (Fig 1D). However, HVEM and CD200 were significantly downregulated
in UM (p = 0.042 and p = 0.005).
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Inflammation drives immune escape in uveal melanoma
The GSE55983 microarray dataset was used to assess the modulation of the genes of interest
upon inflammatory conditions. A trend of increase (p = 0.052) was observed for the MHC
Class I molecules (Fig 2). Also, a significant upregulation in HLA-DOB and HLA-DPA1 was
found (p<0.05). A significant modulation was observed in PDL1 and PDL2 gene expression
levels (p<0.001), that were dramatically increased after incubation with activated T cell super-
natant, as well as in CD47 levels (p<0.05) (Fig 3). It is likely that the increase in expression of
the above-mentioned genes are attributable to the effect of IFN-gamma secreted by activated T
cells, as exposure of 92.1 cells to IFN-gamma (200 ng/ml) was associated to an upregulation of
PDL-1, HLA-A, HLA-DOB and CD47 (S1 Fig).
To evaluate the association of the genes of interest with patients’ and tumor characteristics,
a partial correlation was performed to account for disease status, histological type and adjuvant
therapy. As expected, OS and progression free survival (PFS) resulted significantly correlated
(Table 1). Also, a trend of correlation was observed between mitotic count and tumor diame-
ters (Table 1). PDL1 inversely correlated with OS, PFS and thickness of the tumor. Similarly, a
significant inverse correlation was observed between HLA-A, HLA-B, HLA-H HLA-DPA and
PFS (Table 1). No assessment could be performed for B7-H4, whose expression levels were
below detection sensitivity. A significant correlation was observed in the expression of all the
Fig 1. Immunological profiling of uveal melanoma. A. Venn diagram showing the number of significantly modulated genes in GSE62075 overlapping the “Immune
response” genes (GO:0006955); B. MHC class I gene expression in uveal melanoma as determined in GSE62075; C. MHC class II gene expression in uveal melanoma as
determined in GSE62075; D. Immune checkpoint gene expression in uveal melanoma as determined in GSE62075.
https://doi.org/10.1371/journal.pone.0210276.g001
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Class I and Class II MHC molecules, as well as for MHC genes and PDL1 and PDL2 (Table 2).
Moreover, GAL9 significantly correlated with MHC class I and PDL1 expression (Table 2).
Finally, a significant correlation (p = 0.001) was observed between PDL1 and CD47 expression
levels (Table 2).
Receiver Operating Characteristic (ROC) curves were constructed using disease status
(recurrent disease) as nominal variable. HLA-G resulted to be a significant predictor of recur-
rent disease, with an AUC of 0.810 (p = 0.05) (Fig 4; Table 3). Among the immune-checkpoint
genes, the best predictors found were CD47, with an AUC of 0.781 (p = 0.01); TNFRSF6B,
with an AUC of 0.235 (p = 0.016); CD200 (AUC = 0.242; p = 0.018); HVEM (AUC = 0.163;
p = 0.002); GAL9 (AUC = 0.284; p = 0.049)(Fig 4; Table 3). Accordingly to the ROC analysis,
Kaplan-Meyer analysis revealed that higher levels of the MCH class I molecules—HLA-A,
HLA-G, HLA-H—were associated to significantly lower disease-free survival time (Table 4;
Fig 5). Among the immune checkpoints, low levels of CD47 expression resulted in higher dis-
ease free survival, while higher expression of TNFRSF6B and GAL9 resulted in longer disease
free survival (Table 4; Fig 5).
Discussion
Metastatic UM represents an unmet medical need characterized by extremely poor prognosis
[1,2]. Recently, gene expression and genomic analysis have identified different subsets of uveal
cancer that could propel future efforts to design more individualized and effective treatment
strategies [16]. The immune-based therapeutic strategies, that have increased the overall sur-
vival of cutaneous melanoma patients, have not yet led to significant improvement in unresect-
able/metastatic UM patients [17]. Nevertheless, the growing knowledge of cancer immunology
suggests the possibility of novel therapeutic strategies.
In the present study, we wanted to formally characterize the transcriptomic features regu-
lating the immunogenicity of UM and to determine whether T cell-mediated inflammation is
able to affect the expression profile of genes putatively involved in immune-escape. In compar-
ison to normal uveal melanocytes, significant lower levels of MHC genes were found in UM
cells. Also, most of the inhibitory immune-checkpoints analyzed were not different in uveal
cancer, with the exception of CD200 and HVEM, that resulted significantly reduced. Interest-
ingly, the expression levels of several MHC class I and II molecules, as well as of PDL1 and
Fig 2. Inflammation drives immune escape in uveal melanoma. GSE55983 included data from the three primary human uveal melanoma cell lines, Mel290, Mel270
and 92.1. CD3+ T cells were isolated from whole blood from healthy donors, activated using anti-CD3/CD28 antibodies and cultured in 0.4 μm membrane inserts over
uveal melanoma cell lines, for 64 hours. The expression levels of MHC Class I and II genes have been determined.
https://doi.org/10.1371/journal.pone.0210276.g002
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PDL2 significantly increased under inflammatory conditions. It is reasonable that IFN-gamma
may partly be responsible for the upregulation of these molecules, as in vitro treatment of the
UM cell line, 92.1, with IFN-gamma, was associated to a significant increase in the expression
of these genes (S1 Fig). Also, these observations are in line with previous reports by indepen-
dent Authors who showed that IFN-gamma stimulation is able to affect the expression the
localization of these molecule in UM, in turn resulting in an altered immune response of effec-
tor cells [9,18,19].
It is worth pointing out that our analysis of the TGCA data have been performed account-
ing for the presence of BAP1 mutation as confounding variable. Robertson et al. [20] have
reported that UM with poor prognosis initially develops monosomy 3 (M3-UM), followed by
BAP1 alterations that are associated with a unique global DNA methylation profile. They
reported 4 transcription-based UM subsets, in which one cluster corresponded to M3-UM
with immune infiltration. Also, They showed that a CD8 T cell infiltrate was present in 30% of
M3-UM, while nearly absent in D3-UM, and interferon-gamma signaling (IFNG, IFNGR1,
and IRF1), T cell invasion (CXCL9 and CXCL13), cytotoxicity (PRF1 and GZMA), and immu-
nosuppression (IDO1, TIGIT, IL6, IL10, and FOXP3) were co-expressed with CD8a, suggest-
ing that promotion of an immune environment plays a significant role in aggressive UM, i.e.,
M3 UM. Notably, no significant differences could be found in the expression of the genes here
analyzed between BAP1 mutated and wild type samples (data not shown). In addition, we
have provided data on the expression of the genes analyzed in our paper after stable loss of
BAP1 in three UM cell lines. As it is shown in S2 Fig, the genes analyzed are not significantly
modulated in the BAP1 deficient cell lines, with the exception of PDL-1 and HLA-A with
Fig 3. Inflammation drives immune escape in uveal melanoma. GSE55983 included data from the three primary human uveal melanoma cell lines, Mel290, Mel270
and 92.1. CD3+ T cells were isolated from whole blood from healthy donors, activated using anti-CD3/CD28 antibodies and cultured in 0.4 μm membrane inserts over
uveal melanoma cell lines, for 64 hours. The expression levels of immune-checkpoint genes have been determined.
https://doi.org/10.1371/journal.pone.0210276.g003
Uveal melanoma and immune-escape

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Uveal melanoma and immune-escape


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Uveal melanoma and immune-escape
PLOS ONE | https://doi.org/10.1371/journal.pone.0210276 January 17, 2019 8 / 16
resulted downregulated upon BAP1 loss (p = 0.022 and p = 0.031, respectively). Although
these data may apparently contradict the negative prognostic value of BAP1 loss/mutation,
however, they further support the important role of additional factors in the pathophysiologi-
cal mechanisms underlying tumor growth, immune escape and prognosis in UM.
PDL1 inversely correlated with OS, PFS and thickness of the tumor. These findings have
important clinical implications for the role of immunotherapies in the treatment of patients
with UM. Unfortunately, to date, disappointing results have been obtained from Phase II clini-
cal trials on unresectable/metastatic UM patients treated with the monoclonal antibodies tar-
geting the PD1/PDL1 axis, pembrolizumab, nivolumab or atezolizumab [21]. These results are
generally ascribed to the lack of expression of PDL1 in UM, as determined by independent
Authors. Indeed, Javed et al. [22] have shown that only 5.1% of metastatic UM specimens
expressed PDL1, while Kaunitz et al. [23] found that approximately 10% of UM expressed
PDL1 and only correlated with a moderate–severe grade of CD8+ TILs. The data obtained
from the TGCA database here analyzed confirm the low expression of PDL1, as the mean
mRNA copy number was scarce (mean = 19.2; data not shown). However, the inverse correla-
tion with the clinical data of the patients seem to point to an important role of this gene in
UM. Additional markers of tumor immunogenicity and/or immune checkpoint molecules are
Fig 4. Receiver Operating Characteristic (ROC) curves were constructed for the genes of interest using disease status (recurrent
disease) as nominal variable. Predicted values of the genes of interest were generated using General Linear Model to account for clinical
confounding variables.
https://doi.org/10.1371/journal.pone.0210276.g004
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needed, which may fine-tune the effector activity of tumor-infiltrating T cells and influence
patients’ prognosis. In fact, it is reasonable that functional redundancy occurs between alterna-
tive immune-inhibitory pathways and PDL1, so that combinatorial therapies may reshape the
balance between activation and inhibitory signals received by immune infiltrating cells, thus
restoring effective antitumor T-cell immunity.
It is also notable the inverse correlation between HLA Class 1 genes expression and patients’
survival. This particular data fits in with the trend of increase in MHC expression that we
observed under inflammatory conditions. Our data are in line with van Essen and collabora-
tors (2016) showing that increased HLA class I levels are positively associated to a high infil-
trate of CD3+, and CD68+ leukocytes. Accordingly, these Authors found that UM cells grafted
in SCID-mice (lacking T and B cells) express the HLA class I and II genes at a much lower
extent than their original counterpart [24]. Moreover, lack of HLA class I expression correlates
with higher OS [25]. It is likely that this strategy may allow the tumor to escape the immune
surveillance by NK cells [25], while the increase in PDL1 may block CTL response [25].
From the ROC and Kaplan-Meier analysis, a potential prognostic value for GAL9 and
TNFRSF6B was also determined. However, the role of these genes in UM is still elusive. In
fact, despite their immune-suppressive properties, we found that higher levels of expression
Table 3. Data from Receiver Operating Characteristic (ROC) curves generated for the genes of interest using dis-
ease status (recurrent disease) as nominal variable. Predicted values of the genes of interest were generated using
General Linear Model to account for clinical confounding variables.
Area Under the Curve
Test Result Variable(s) Area Std. Error Asymptotic Sig. Asymptotic 95% Confidence
Interval
Lower Bound Upper Bound
Predicted Value for HLAA .667 .101 .128 .468 .865
Predicted Value for HLAB .585 .101 .438 .386 .784
Predicted Value for HLAC .542 .107 .698 .332 .753
Predicted Value for HLAF .533 .105 .765 .327 .739
Predicted Value for HLAG .810 .069 .005 .674 .947
Predicted Value for HLAH .706 .102 .060 .506 .906
Predicted Value for HLADMA .497 .105 .976 .292 .702
Predicted Value for HLADMB .408 .114 .403 .185 .632
Predicted Value for HLADOA .575 .098 .492 .382 .768
Predicted Value for HLADOB .369 .109 .232 .156 .582
Predicted Value for HLADPA .523 .104 .834 .319 .727
Predicted Value for HLADQA1 .598 .104 .370 .395 .801
Predicted Value for HLADQB1 .454 .108 .676 .243 .665
Predicted Value for HLADRA .487 .106 .905 .280 .694
Predicted Value for PDL1 .572 .108 .511 .360 .784
Predicted Value for PDL2 .382 .122 .282 .144 .621
Predicted Value for B7H3 .320 .114 .101 .096 .545
Predicted Value for B7H4 .644 .113 .189 .423 .865
Predicted Value for TNFRSF6B .235 .084 .016 .070 .401
Predicted Value for GAL9 .284 .085 .049 .117 .452
Predicted Value for CD47 .781 .102 .010 .580 .982
Predicted Value for CD200 .242 .076 .018 .094 .390
Predicted Value for HVEM .163 .063 .002 .040 .287
Predicted Value for CD155 .676 .112 .107 .457 .896
https://doi.org/10.1371/journal.pone.0210276.t003
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Table 4. For Kaplan-Meier analysis, predicted values of the genes of interest were generated using General Linear
Model to account for clinical confounding variables and were dichotomized using median value as cut-off. For
each gene, Log-rank (Mantel-Cox) analysis was performed to assess statistical differences in Progression-Free Survival













60.849 10.617 40.040 81.658 5.316044951 0.021129918
High
expression
33.412 4.032 25.509 41.315
HLAB_predicted Low
expression
55.946 10.201 35.952 75.939 0.869944517 0.350970669
High
expression
37.788 3.113 31.685 43.890
HLAC_predicted Low
expression
55.442 10.217 35.417 75.468 0.651291391 0.419651352
High
expression
37.976 2.947 32.201 43.751
HLAF_predicted Low
expression
53.142 9.316 34.883 71.400 0.171876007 0.678449895
High
expression
36.567 2.563 31.544 41.589
HLAG_predicted Low
expression
77.906 4.068 69.933 85.880 5.92839856 0.014898775
High
expression
36.197 4.697 26.991 45.403
HLAH_predicted Low
expression
61.117 10.602 40.337 81.897 5.989849457 0.01438843
High
expression
32.887 4.265 24.528 41.246
HLADMA_predicted Low
expression
52.667 9.338 34.365 70.970 0.082972562 0.773308785
High
expression
36.747 2.424 31.996 41.498
HLADMB_predicted Low
expression
52.146 9.366 33.789 70.503 0.002775545 0.957984135
High
expression
37.265 2.248 32.858 41.672
HLADOA_predicted Low
expression
55.442 10.217 35.417 75.468 0.651291391 0.419651352
High
expression
37.976 2.947 32.201 43.751
HLADOB_predicted Low
expression
50.167 9.126 32.281 68.054 0.389689022 0.53246291
high
expression
39.300 1.184 36.979 41.621
HLADPA_predicted Low
expression
54.889 10.239 34.820 74.958 0.470277913 0.492859343
High
expression
38.138 2.806 32.638 43.638
HLADQA1_predicted Low
expression
57.875 10.408 37.476 78.274 2.255889815 0.133106926
high
expression
35.569 3.732 28.254 42.883
(Continued)
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are associated to better PFS. GAL9 encodes for a protein with affinity to bind β-galactoside
and that possess carbohydrate recognition domains [26]. It was previously shown that GAL9,
via interacting with TIM-3, is able to negatively regulate Th1 responses, to induce apoptosis of
CTLs and to promote suppressive activity of Tregs. On the other hand, in a preclinical model
of melanoma, GAL9 was found to expand plasmacytoid cell-like macrophages, thus increasing
the NK-mediated cytolysis of cancer cells. Therefore, GAL9 may exert pleiotropic effects in
cancer and the prognostic value of this gene in cancer remains controversial. In fact, a meta-














52.947 9.253 34.811 71.082 0.132323225 0.716035297
High
expression
36.112 2.963 30.304 41.920
HLADRA_predicted Low
expression
54.889 10.239 34.820 74.958 0.470277913 0.492859343
High
expression
38.138 2.806 32.638 43.638
PDL1_predicted Low
expression
58.256 10.422 37.829 78.684 2.587052616 0.107740658
High
expression
35.469 3.734 28.150 42.788
PDL2_predicted Low
expression
53.142 9.316 34.883 71.400 0.171876007 0.678449895
High
expression
36.567 2.563 31.544 41.589
B7H3_predicted Low
expression
47.795 9.010 30.135 65.454 1.235888265 0.266264959
High
expression
43.523 1.969 39.663 47.383
TNFRSF6B_predicted Low
expression
36.302 4.726 27.039 45.564 5.737360787 0.016607729
High
expression
77.909 4.072 69.927 85.892
GAL9_predicted Low
expression
37.204 4.571 28.244 46.164 4.368411636 0.036611103
High
expression
75.214 6.375 62.719 87.709
CD47_predicted Low
expression
63.613 10.808 42.430 84.796 9.483907795 0.00207282
High
expression
31.139 4.341 22.630 39.647
HVEM_predicted Low
expression
46.037 8.365 29.642 62.431 2.86334347 0.090618963
High
expression
45.926 1.856 42.289 49.563
CD155_predicted Low
expression
46.192 4.012 38.328 54.056 1.343753464 0.24637312
High
expression
47.095 10.294 26.920 67.271
https://doi.org/10.1371/journal.pone.0210276.t004
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high GAL9 expression was associated to improved overall survival, and was significantly corre-
lated with smaller depth of invasion, earlier histopathological stage, negative lymph node
metastasis and negative distal tumor metastasis [26].
TNFRSF6B is a member of the tumor necrosis factor receptor superfamily that acts as a
decoy receptor for the apoptosis-inducing proteins Fas ligand (FasL), lymphotoxin analogues
(LIGHT), and tumor necrosis factor-like ligand 1A (TL1A). In solid tumors, TNFRSF6B over-
expression has been significantly associated with worse OS in patients with solid tumors, but
its expression does not influence recurrence-free survival [27]. Additional functional data are
needed to decipher the exact role of TNFRSF6B in regulating cancer recurrence, immune
response to cancer and patients’ survival in UM.
Finally, for the first time, we propose a possible role for CD47 in the immune evasive prop-
erties of UM. CD47 is a molecule with an immunoglobulin-like domain that is expressed on
tumor cell surface and inhibits macrophage phagocytosis via binding the signal regulatory pro-
tein α (SIRPα) on phagocytes [28]. In gastric cancer, CD47 expression is an independent nega-
tive prognostic factor for gastric cancer, and in ovarian cancer, it is associated with adverse
clinical characteristics and a poor prognosis [28]. We show here that CD47 is significantly
upregulated by UM cells following inflammatory stimuli and that it represents a good indepen-
dent predictor of disease progression. Anti-CD47-targeted therapy may represent a promising
strategy to treat cancer and to improve long-term survival. A number of potent CD47 inhibi-
tors are currently available (e.g. Hu5F9-G4, CC-90002, TTI-621, NI-1701, NI-1801, SRF231)
Fig 5. For Kaplan-Meier analysis, predicted values of the genes of interest were generated using General Linear Model to account for clinical confounding
variables and were dichotomized using median value as cut-off. For each gene, Log-rank (Mantel-Cox) analysis was performed to assess statistical differences in
Progression-Free Survival time between patients with Low and High expression. Only graphs for significant data are shown.
https://doi.org/10.1371/journal.pone.0210276.g005
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and some of them are already under clinical investigation in human solid and hematological
cancers [28].
Our in silico analysis highlights the complex pattern of gene expression that may orchestrate
the interaction between UM cells and the immune cells and warrants further investigation
aimed at exploring more focused pathogenic-tailored immunotherapeutic approaches in
patients with UM.
Supporting information
S1 Fig. IFN-gamma drives immune escape in uveal melanoma. The uveal melanoma 92.1
cells were exposed for 72 hrs to recIFN-gamma 200 ng/ml and the expression levels of the
HLA-A, HLA-DOB, PDL-1 PDL-2 and CD47 genes were determined by Real-time PCR.
Primer pairs sequences were obtained from the PrimerBank database. The data are presented
as fold change increase with respect to unstimulated control cells and CI 95%. Statistical differ-
ences have been determined by two-tailed unparired Student’s t test using the GrapPad Prism
software.
(TIF)
S2 Fig. BAP1 loss does not affect the expression of immune evading genes in uveal mela-
noma. To determine whether stable loss of the BAP1 gene altered the immunological profiling
of uveal melanoma, the GSE48863 microarray dataset was analyzed. GSE48863 included data
from the three human uveal melanoma cell lines, 92.1, Mel290, and OCM1a, that were stably
depleted using shRNA for either BAP1 or the control gene GFP. Cells were grown under puro-
mycin selection for 4 weeks after lentiviral infection and microarray was performed using the
Illumina HumanHT-12 V4.0 expression beadchip platform. Two biological replicates were
performed for each cell line. An heatmap showing the expression levels of the genes of interest
as fold change with respect to the relative control cells is presented. The heatmap is color
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